Drug Discovery & Development
News on drug screening, clinical trials, companion diagnostics, immunotherapy, & personalized therapies in genetics, genomics, and molecular diagnostics.
European Society for Medical Oncology Congress 2021: Precision Oncology Data Roundup
Researchers presented data at the meeting on biomarker-directed therapies and tests to characterize patients' responses to cancer treatment.Â
Rain Therapeutics' Milademetan Shows Clinical Activity in MDM2-Amplified Intimal Sarcoma
Data presented at the ESMO Congress provided proof of concept for MDM2 inhibition in patients with these ultra-rare sarcomas and limited treatment options.
Salarius, Fox Chase Cancer Center to Explore New Indications, Biomarkers for Seclidemstat
The drugmaker is partnering with the Cancer Epigenetics Institute to identify new therapeutic opportunities for the drug in LSD1-driven solid tumors.
Erasca Begins Phase Ib/II Master Protocol Trial of ERAS-007 in Gastrointestinal Cancers
The company will initially study the ERK1/2 inhibitor in combination with other therapies in biomarker-defined advanced colorectal cancers.
Oncologists Bemoan 'Lousy' PD-L1 Biomarker in Light of New Adjuvant Tecentriq NSCLC Study Data
Premium
Updated results from IMpower010 showed NSCLC patients with PD-L1 expression in 1 to 49 percent of tumor cells derived less benefit from adjuvant Tecentriq than those with higher expression.